REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

Boehringer Ingelheim reports record productivities for CHO cells

November 09. A team of Boehringer Ingelheim scientists reports another milestone in the development of the BI-HEX® technology platform. A record productivity of more than 100 picogramms per cell per day was achieved in inoculum and fed-batch cultures of BI-HEX® Chinese hamster ovary (CHO) cell lines expressing a therapeutic monoclonal antibody.
At this point the most recent result coming out from the BI-HEX® platform suggests that another leap in productivity is indeed possible. Combining sophisticated vector set-ups with rigorous high-throughput screenings enabling rapid selection of high-producer cell lines under process conditions and the latest version of a Boehringer Ingelheim proprietary media and feed platform led to the generation of cell lines that produce previously unreported amounts of an IgG molecule during inoculum culture and in a scalable fed-batch format.

 

Boehringer Ingelheim is one of the world’s leading manufacturers for producing therapeutic proteins from mammalian cell culture. As a true ‘one-stop-shop’ (from the genetic engineering up to the launch of a biopharmaceutical) Boehringer Ingelheims biotechnology site in Biberach/Riss (Germany) offers more than 100.000 liters of GMP cell culture capacity, more than 20 years of process and regulatory experience and its BI-HEX® CHO platform shaping the state-of-the-art of the industry for many years.
The success of therapeutic antibodies produced from mammalian cell culture in the clinic and on the market has fuelled a race to increase cellular productivities for many years with scientists all over the world asking at what point fundamental limits would be reached.
 ‘We are enthusiastic about the new proof that our BI-HEX® technology platform continues to revolutionize the biopharma landscape leading to antibody productivities in industrial relevant CHO processes beyond that magic boundary of 100 picogramms per cell per day,’ states Professor Rolf Werner, Senior Vice President of the Corporate Division Biopharmaceuticals at Boehringer Ingelheim.  ‘We are particularly encouraged by this result, as we obtained the data without any cell-line specific process optimization’, adds Dr. Lore Florin who is leading a team of scientists reporting the new record productivities. Boehringer Ingelheim will continue to develop BI-HEX® and expects further improvements to be reported in the near future.
____________________________________________________________________________
Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.

Top 10 Tags

All Tags (2094)